Many pharmaceutical developers of generic orally inhaled products (OIPs) are facing significant issues in passing the regulatory requirement to show pharmacokinetic (PK) bioequivalence (BE) to the originator product. The core of the issue is that no reliable in vitro-in vivo correlation (IVIVC) is available to guide their development. In this paper, several issues are identified and means to improve the data used for developing an IVIVC are discussed. The article also presents an "IVIVC-free" approach for developing a formulation matching the originator's PK performance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.addr.2021.113895 | DOI Listing |
Publication Analysis
Top Keywords
bioequivalence assessment
4
assessment pharmaceutical
4
pharmaceutical aerosol
4
aerosol products
4
products ivivc
4
ivivc pharmaceutical
4
pharmaceutical developers
4
developers generic
4
generic orally
4
orally inhaled
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!